1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Delayed Xetra  -  11:35 2022-08-12 am EDT
54.15 EUR   +4.78%
08/12Arbitral Tribunal Sides With Bayer in Breach of Contract Case from BASF
MT
08/12BAYER AG : JP Morgan gives a Buy rating
MD
08/12Bayer Shares Climb After Arbitration Tribunal Dismisses BASF Claims
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer wins fourth Roundup weedkiller case in U.S

06/18/2022 | 03:05am EDT
FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

FRANKFURT (Reuters) - A U.S. jury found Bayer's Roundup weedkiller did not cause an Oregon man's cancer, the German agriculture and pharmaceuticals company said on Saturday, handing the firm its fourth consecutive trial victory over such claims.

The verdict, reached on Friday by the Circuit Court of Jackson County, Oregon, is "consistent with the assessments of expert regulators worldwide as well as the overwhelming evidence from four decades of scientific studies concluding that Roundup can be used safely and is not carcinogenic", Bayer said.

"We continue to stand behind the safety of Roundup and will confidently defend the safety of our product as well as our good faith actions in any future litigation."

Glyphosate is the active ingredient in Bayer brands such as Roundup and RangerPro. It has been at the centre of mass litigation in the United States brought mostly by residential gardeners claiming the weedkiller caused their cancer.

The company has spent billions of dollars to settle close to 100,000 Roundup cases.

(Reporting by Christoph Steitz; Editing by Mark Potter)


© Reuters 2022
All news about BAYER AG
08/12Arbitral Tribunal Sides With Bayer in Breach of Contract Case from BASF
MT
08/12BAYER AG : JP Morgan gives a Buy rating
MD
08/12Bayer Shares Climb After Arbitration Tribunal Dismisses BASF Claims
DJ
08/12BAYER : statement on the decision in the BASF arbitration proceedings
PU
08/12Bayer welcomes ruling against BASF claim on seed businesses
RE
08/12Chasing green goals, corporations push car fleet managers toward EVs
RE
08/11GSK, Sanofi and Haleon shares slump on Zantac litigation concerns
RE
08/11BAYER : Showcases Leadership in Breakthrough Innovations and Sustainable, Tailored Solutio..
PU
08/11GSK, Sanofi and Haleon shares slump on Zantac litigation concerns
RE
08/09Mexican President says Bayer interested in continuing to invest in country
RE
More news
Analyst Recommendations on BAYER AG
More recommendations
Financials
Sales 2022 49 174 M 50 420 M 50 420 M
Net income 2022 4 988 M 5 114 M 5 114 M
Net Debt 2022 33 508 M 34 357 M 34 357 M
P/E ratio 2022 11,0x
Yield 2022 4,21%
Capitalization 53 198 M 54 546 M 54 546 M
EV / Sales 2022 1,76x
EV / Sales 2023 1,70x
Nbr of Employees 101 914
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 54,15 €
Average target price 78,64 €
Spread / Average Target 45,2%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG15.21%54 546
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131